Verition Fund Management
EFTR

Verition Fund Management’s eFFECTOR Therapeutics, Inc. Common Stock EFTR Stock Holding History

Verition Fund Management’s Portfolio EFTR Stock Details EFTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-987
Closed -$347K – 2872
2021
Q3 		$347K Buy
+987
New +$318K ﹤0.01% 1401

Other funds holding EFTR

SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
CG
Column Group San Francisco, California $88.1M AUM 148.03% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $143M AUM 102.52% 1-Year Est. Return
OMC
OUP Management Company Bala Cynwyd, Pennsylvania $44.5M AUM 55.11% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AA
ALPS Advisors Denver, Colorado $21.3B AUM 23.41% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Verition Fund Management's EFTR Position: Q4 2021 in Review

Verition Fund Management sold out of eFFECTOR Therapeutics, Inc. Common Stock (EFTR) in Q4 2021, closing a stake of 987 shares — an estimated $347K sold.

Verition Fund Management first reported a position in EFTR in Q3 2021 and held it in 1 quarter. The position peaked at $347K in Q3 2021. 18 funds tracked by Wall St. Rank hold EFTR as of Q4 2021.

  • Verition Fund Management reported no remaining eFFECTOR Therapeutics, Inc. Common Stock position as of Q4 2021 after selling out during the quarter.
  • Verition Fund Management sold 987 eFFECTOR Therapeutics, Inc. Common Stock shares in Q4 2021, an estimated $347K.
  • Verition Fund Management first reported a position in eFFECTOR Therapeutics, Inc. Common Stock in Q3 2021 and held it in 1 quarter.
  • Verition Fund Management's eFFECTOR Therapeutics, Inc. Common Stock position peaked at $347K in Q3 2021.
  • 18 funds tracked by Wall St. Rank held eFFECTOR Therapeutics, Inc. Common Stock as of Q4 2021.

Based on Verition Fund Management's 13F filing for Q4 2021, filed 14 Feb 2022.